跳至主要内容
临床试验/JPRN-jRCTs051220028
JPRN-jRCTs051220028进行中(未招募)未知

Investigation of the Mechanism of Action of imeglimin in Japanese Patients with Type 2 Diabetes-delineation of the profile of imeglimins mechanism using glucose clamp test

Sakaguchi Kazuhiko0 个研究点目标入组 30 人开始时间: 2022年5月25日最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 75age old(—)
性别
All

入选标准

  • (1)Patients between 20 and 75 years old
  • (2)Patients diagnosed with type 2 diabetes mellitus
  • (3)BMI of the patients more than 18.5 kg/m2
  • (4)Patients who have been taking only diet and ex ercise therapy or only dipeptidyl peptidase 4 (DPP 4) inhibitors without changing the dosage and ad ministration for the treatment of diabetes for at least 8 weeks prior to obtaining consent
  • (5)Patients whose HbA1c is less than 9.5 % at the time of eligibility test
  • (6)Patients who have given their free and written consent to participate in this clinical research

排除标准

  • (1)Patients using insulin, GLP-1RA, or oral hypoglycemic agents other than DPP4 inhibitors
  • (2)Patients with severe hepatic dysfunction (AST/ALT greater than 4 times the upper limit of normal)
  • (3)Patients with renal dysfunction (eGFR less than 45 mL/min/1.73m2)
  • (4)Patients who have undergone gastrectomy (not including endoscopic mucosal resection)
  • (5)Patients with proliferative diabetic retinopathy ( except for patients with obsolete proliferative diabetic retinopathy that does not require treatment)
  • (6)Patients with severe diabetic neuropathy (patients whose symptoms are so severe that they seriously interfere with daily life and require assistance)
  • (7)Patients with a cardiac function classification of grade 3 or 4 according to NYHA at an evaluation within the last year
  • (8)Patients who drink excessively and habitually
  • (9)Patients with a history of lactic acidosis
  • (10)Patients with a history of severe ketosis, diabetic coma, or precoma
  • (11)Patients who have undergone major surgery within one month
  • (12)Patients with severe infection or serious trauma
  • (13)Patients with malignant tumors under treatment or within 5 years of completion of treatment
  • (14)Pregnant women, lactating women, and patients who may be or are planning to become pregnant
  • (15)Patients who have used antibiotics or antiparasitic drugs within one month prior to eligibility confirmation
  • (16)Patients who have taken PPI (proton pump inhibitor), steroids, or immunosuppressive drugs within one month prior to eligibility confirmation
  • (17)Patients with lower gastrointestinal diseases ( Crohn's disease, ulcerative colitis, short bowel syndrome, celiac disease, etc.)
  • (18)Patients who are participating in clinical research involving other interventions(However, participation in the Study to evaluate intestinal FDG accumulation on 18F-FDG-PET/MRI in patients taking imegurimine or metformin is acceptable)
  • (19)Patients who are judged by the principal investigator or sub-investigator to be inappropriate for this clinical research

研究者

发起方
Sakaguchi Kazuhiko

相似试验